Corcept Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Corcept Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Corcept Therapeutics Inc
Rating: 2.061555625
Author: Trendlyne DVM scores

Expensive Performer

about

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The ...

71.41 -1.36 (-1.87%)

39.14% Fall from 52W High

1.0M

XNAS Volume

XNAS 15 Jul, 2025 5:30 PM (EDT)

Medium Financial Strength

38.9 / 100

Expensive Valuation

28.7 / 100

Technically Neutral

58.5 / 100

Expensive Performer These stocks are with medium quality and mid-range technical aspects. However, their financials make them little expensive so choose the right moment to buy them. View Similar Embed DVM

138

1Yr Price target upside is 94%

4 analysts

Corcept Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Corcept Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The ...

39.14% Fall from 52W High

SWOT Analysis

Corcept Therapeutics Inc Live Price Chart